Zafgen (NASDAQ:ZFGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, ValuEngine raised shares of Zafgen from a “strong sell” rating to a “sell” rating in a research report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. Zafgen presently has a consensus rating of “Hold” and a consensus target price of $6.63.

Shares of Zafgen (NASDAQ:ZFGN) traded down $0.04 on Friday, hitting $5.56. 111,654 shares of the stock traded hands, compared to its average volume of 155,300. The company has a market capitalization of $153.94, a price-to-earnings ratio of -3.07 and a beta of -1.25. Zafgen has a 52 week low of $3.21 and a 52 week high of $5.75.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.12. analysts anticipate that Zafgen will post -2.02 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in ZFGN. Mangrove Partners bought a new position in Zafgen during the third quarter worth about $1,971,000. Goldman Sachs Group Inc. increased its position in Zafgen by 1,701.5% during the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after acquiring an additional 186,336 shares during the period. Dimensional Fund Advisors LP increased its position in Zafgen by 31.8% during the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 140,848 shares during the period. Vanguard Group Inc. increased its position in Zafgen by 15.7% during the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after acquiring an additional 119,902 shares during the period. Finally, OxFORD Asset Management LLP bought a new position in Zafgen during the second quarter worth about $364,000. 48.60% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/13/zafgen-zfgn-downgraded-to-hold-at-zacks-investment-research.html.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.